Positron emission tomography in mantle cell lymphoma

References

• Lenz G, Dreyling M, Hiddemann W. Mantle cell lymphoma: established therapeutic options and future directions. Ann Hematol 2004; 83: 71–77
   PubMed Web of Science ®Google Scholar
• Weigert O, Unterhalt M, Hiddemann W, Dreyling M. Current management of mantle cell lymphoma. Drugs 2007; 67: 1689–1702
   PubMed Web of Science ®Google Scholar
• Jacobsen E, Freedman A. An update on the role of high-dose therapy with autologous or allogeneic stem cell transplantation in mantle cell lymphoma. Curr Opin Oncol 2004; 16: 106–113
   PubMed Web of Science ®Google Scholar
• Tiemann M, Schrader C, Klapper W, Dreyling M H, Campo E, Norton A, et al. Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinicopathological study from the European MCL Network. Br J Haematol 2005; 131: 29–38
   PubMed Web of Science ®Google Scholar
• Bosch F, Lopez-Guillermo A, Campo E, Ribera J M, Conde E, Piris M A, et al. Mantle cell lymphoma. Presenting features, response to therapy, and prognostic factors. Cancer 1997; 82: 567–575
   Web of Science ®Google Scholar
• Argatoff L H, Connors J M, Klasa R J, Horsman D E, Gascoyne R D. Mantle cell lymphoma: a clinicopathologic study of 80 cases. Blood 1997; 89: 2067–2078
   PubMed Web of Science ®Google Scholar
• Bernard M, Gressin R, Lefrère F, Drénou B, Branger B, Caulet-Maugendre S, et al. Blastic variant of mantle cell lymphoma: a rare but highly aggressive subtype. Leukemia 2001; 15: 1785–1791
   PubMed Web of Science ®Google Scholar
• Brepoels L, Stroobants S, de Wever W, Spaepen K, Vandenberghe P, Thomas J, et al. Hodgkin lymphoma: Response assessment by Revised International Workshop Criteria. Leuk Lymphoma 2007; 48: 1539–1547
   PubMed Web of Science ®Google Scholar
• Brepoels L, Stroobants S, De Wever W, Spaepen K, Vandenberghe P, Thomas J, et al. Aggressive and indolent non-Hodgkin's lymphoma: Response assessment by Integrated International Workshop Criteria. Leuk Lymphoma 2007; 48: 1522–1530
   PubMed Web of Science ®Google Scholar
• Tsukamoto N, Kojima M, Hasegawa M, Oriuchi N, Matsushima T, Yokohama A, et al. The usefulness of (18)F-fluorodeoxyglucose positron emission tomography ((18)F-FDG-PET) and a comparison of (18)F-FDG-pet with (67)gallium scintigraphy in the evaluation of lymphoma: relation to histologic subtypes based on the World Health Organization classification. Cancer 2007; 110: 652–659
   PubMed Web of Science ®Google Scholar
• Elstrom R, Guan L, Baker G, Nakhoda K, Vergilio J A, Zhuang H, et al. Utility of FDG-PET scanning in lymphoma by WHO classification. Blood 2003; 101: 3875–3876
   PubMed Web of Science ®Google Scholar
• Karam M, Matthew J, Shet N, Ashar Ata. FDG-PET study may identify mantle cell lymphoma patients with an unusually favourable prognosis. J Nucl Med 2007; 48: 148P, (abstr 504)
   Google Scholar
• Harris N L, Jaffe E S, Diebold J, Flandrin G, Muller-Hermelink H K, Vardiman J, et al. The World Health Organization classification of neoplastic diseases of the haematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997. Histopathology 2000; 36: 69–86
   PubMedGoogle Scholar
• Dreger P, Martin S, Kuse R, Sonnen R, Glass B, Kröger N, et al. The impact of autologous stem cell transplantation on the prognosis of mantle cell lymphoma: a joint analysis of two prospective studies with 46 patients. Hematol J 2000; 1: 87–94
   PubMedGoogle Scholar
• De Wever W, Vankan Y, Stroobants S, Verschakelen J. Detection of extrapulmonary lesions with integrated PET/CT in the staging of lung cancer. Eur Respir J 2007; 29: 995–1002
   PubMed Web of Science ®Google Scholar
• Cheson B D, Pfistner B, Juweid M E, Gascoyne R D, Specht L, Horning S J, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 10;25: 579–586
   Web of Science ®Google Scholar
• Young H, Baum R, Cremerius U, Herholz K, Hoekstra O, Lammertsma A A, et al. Measurement of clinical and subclinical tumour response using 18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. Eur J Cancer 1999; 35: 1773–1782
   PubMed Web of Science ®Google Scholar
• Juweid M E, Stroobants S, Hoekstra O S, Mottaghy F M, Dietlein M, Guermazi A, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 2007; 25: 571–578
   PubMed Web of Science ®Google Scholar
• Kaplan E S, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958; 58: 457–481
   Google Scholar
• Pott C, Schrader C, Brüggemann M, Ritgen M, Harder L, Raff T, et al. Blastoid variant of mantle cell lymphoma: late progression from classical mantle cell lymphoma and quantitation of minimal residual disease. Eur J Haematol 2005; 74: 353–358
   PubMed Web of Science ®Google Scholar
• Bruzzi J F, Macapinlac H, Tsimberidou A M, Truong M T, Keating M J, Marom E M, Munden R F. Detection of Richter's transformation of chronic lymphocytic leukemia by PET/CT. J Nucl Med 2006; 7: 1267–1273
   Google Scholar
• Howard O M, Gribben J G, Neuberg D S, Grossbard M, Poor C, Janicek M J, Shipp M A. Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival. J Clin Oncol 2002; 20: 1288–1294
   PubMed Web of Science ®Google Scholar
• de Geus-Oei L F, van der Heijden H F, Corstens F H, Oyen W J. Predictive and prognostic value of FDG-PET in nonsmall-cell lung cancer: a systematic review. Cancer 2008; 110: 1654–1664
   Web of Science ®Google Scholar
• Jerusalem G, Beguin Y, Fassotte M F, Belhocine T, Hustinx R, Rigo P, Fillet G. Early detection of relapse by whole-body positron emission tomography in the follow-up of patients with Hodgkin's disease. Ann Oncol 2003; 14: 123–130
   PubMed Web of Science ®Google Scholar